PurMinds Announces Clinical Validation Collaboration with SpectroChip and Taiwan's Kaohsiung Municipal Siaogang Hospital

(OTC:PFSF) PurMinds Enterprises, Inc. announced the signing of a five-year collaboration agreement with SpectroChip Inc. and Kaohsiung Municipal Siaogang Hospital to advance point-of-care (POC) diagnostics, clinical performance evaluation, and precision-medicine applications. The collaboration will establish the "PurMinds / SpectroChip Global Clinical Validation Testing Center" for teaching, research, and clinical-validation activities, subject to institutional review board (IRB) review, institutional approvals, and regulatory requirements. PurMinds will lead precision-medicine applications, clinical research collaboration, and access to international research and industry resources as part of its global commercialization strategy. SpectroChip will provide its photonic chip-based testing technology, technical documentation, training, and related support. Siaogang Hospital will provide an institutional setting for approved teaching, research, and clinical-validation activities, including research design, performance evaluation, testing-workflow assessment, and talent development. Specific research projects will be established through separate written arrangements defining scope, responsibilities, timelines, funding, and deliverables. Activities involving human participants, specimens, personal data, or medical-device clinical studies will comply with ethical, regulatory, and institutional requirements. The collaboration does not create a separate legal entity or dedicated physical facility. SpectroChip has committed to providing Siaogang Hospital with NT$3 million (about US$94,000) in teaching and research funding over five years, generally at NT$600,000 per year, subject to agreement and institutional procedures. The funding will support approved educational and research activities, including research consumables, testing, equipment maintenance, data analysis, research personnel, training, and academic exchange. The hospital retains independence in professional, clinical, research, and procurement decisions. Janet Qi, Founder and Chief Executive Officer of PurMinds, stated that the collaboration brings together SpectroChip's photonic chip technology, Siaogang Hospital's clinical research environment, and PurMinds' precision-medicine platform and commercialization strategy. Dr. Cheng-Hao (Kevin) Ko, founder of SpectroChip and inventor of the SwiftLab Platform, highlighted the opportunity to systematically evaluate diagnostic performance and testing workflows in a clinical research environment. Chih-Hsing Hung, MD, PhD, Dean of Kaohsiung Municipal Siaogang Hospital, emphasized the importance of collaboration between healthcare institutions, technology developers, and market integrators for responsible evaluation of emerging diagnostic technologies. PurMinds' SwiftLab Platform is built around a full-spectrum laboratory-grade spectrometer on a photonic chip, housed in the SpectroCision™ SPU-D100 portable reader, designed to deliver quantitative results from low-cost lateral-flow cassettes in five minutes or less. PurMinds holds an exclusive license to the SwiftLab Platform for health and safety fields worldwide. PurMinds' two drug candidates, PUR102 (a botanical psilocybin) and PUR501 (a preclinical non-hallucinogenic neuroplastogen), are held in its wholly owned subsidiary, PurQuest™ Therapeutics. The SpectroCision reader and PurMinds cassettes have not been cleared or approved by the United States Food and Drug Administration or licensed by Health Canada and are not available for clinical use in the United States or Canada.

PurMinds Enterprises, Inc. Files Fiscal 2026 Second Quarter Financials on OTC Markets; Launches PCAOB Audit to Position for OTCQB/QX Uplisting

(OTC:PFSF) PurMinds Enterprises, Inc. announced the formal submission, on May 20, of its financials for the fiscal second quarter ended March 31, 2026, on OTCMarkets.com. The Company achieved the formal cancellation and return of 1,500,000 legacy common shares, the complete redemption and retirement of all outstanding Series A Preferred stock, and the cancellation of 1,000 Series B Preferred shares. The Company finalized the complete settlement and elimination of $300,000 in legacy promissory note liabilities. Total private capital raised or formally committed since the inception of the RTO has exceeded $2.25 million, including $2,101,781 under Regulation S and $40,000 under Regulation D during March 2026, with subsequent post-quarter cash receipts of $428,037 (Reg S) and $125,000 (Reg D) through May 20, 2026. Revenue and gross profit were zero, unchanged vs. Q2 of fiscal 2025, while total operating expenses in Q2 fiscal 2026 increased by $500,000 to $814,000, mainly due to a $350,000 charge for R&D and licensing fees. Net loss was $922,000, or $(.00) per share, vs. a net loss of $182,000, or $(.00) per share, in Q2 of the prior fiscal year. The company projects the entire audit process is expected to be completed by the end of June or early July 2026, and management targets achieving targeted clinical milestones over the next 24 months.